Acutus Medical Inc (OTCPK:AFIB)

$ 0.055 0.003 (5.77%) Market Cap: 1.65 Mil Enterprise Value: 24.74 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q2 2023 Acutus Medical Inc Earnings Call Transcript
Aug 07, 2023

$0.676 (-2.03%)

Earnings
Q1 2023 Acutus Medical Inc Earnings Call Transcript
May 11, 2023

$0.9494 (-1.12%)

Earnings
Acutus Medical Inc To Discuss Results From RECOVER AF Study Transcript
Apr 21, 2023
Q4 2022 Acutus Medical Inc Earnings Call Transcript
Mar 16, 2023

$1 (+11.11%)

Earnings
Q3 2022 Acutus Medical Inc Earnings Call Transcript
Nov 10, 2022

$0.7521 (-1.05%)

Earnings
Q2 2022 Acutus Medical Inc Earnings Call Transcript
Aug 11, 2022

$1.66 (+3.11%)

Earnings
Q1 2022 Acutus Medical Inc Earnings Call Transcript
May 12, 2022

$0.94 (+5.00%)

Earnings
Acutus Medical Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Q4 2021 Acutus Medical Inc Earnings Call Transcript
Mar 30, 2022

$1.93 (+1.58%)

Earnings
Q3 2021 Acutus Medical Inc Earnings Call Transcript
Nov 11, 2021

$6.66 (-9.88%)

Earnings
Q2 2021 Acutus Medical Inc Earnings Call Transcript
Aug 12, 2021

$13.29 (-7.77%)

Earnings
Acutus Medical Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021
Q1 2021 Acutus Medical Inc Earnings Call Transcript
May 12, 2021

$11.59 (-2.77%)

Earnings
Q4 2020 Acutus Medical Inc Earnings Call Transcript
Mar 18, 2021

$16.83 (-11.70%)

Earnings
Acutus Medical Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 Acutus Medical Inc Earnings Call Transcript
Nov 12, 2020

$24.61 (+1.07%)

Earnings
Q2 2020 Acutus Medical Inc Earnings Call Transcript
Sep 17, 2020

$34.51 (-2.68%)

Earnings

Acutus Medical Inc To Discuss Results From RECOVER AF Study Transcript

Apr 21, 2023 / 04:00PM GMT

Release Date Price: $0.789 (+6.62%)

Transcript 8-K

Operator

Thank you for standing by. Welcome to Acutus Medical RECOVER AF study results conference call. (Operator Instructions). Please be advised that today's conference is being recorded. I would now like to hand the conference over to David Roman, Chief Executive Officer. Please go ahead.

David Harrison Roman

Acutus Medical, Inc. - CEO, President & Director

Thank you, Justin. Good afternoon, and thank you to everyone joining us today. I'm very excited to have this opportunity to share additional perspective on the RECOVER AF study results that were published earlier this week online in EP Europace. We are especially privileged to have Professor Tim Betts joining us today who was the principal investigator in this key study.

Professor Betts is a Professor of Cardiology at Oxford University Hospital and has been a long-time investigator and supporter of Acutus Medical throughout our journey to bring innovative solutions to treat the most complex of arrhythmia patients. During today's call, Professor Betts will provide a brief summary of the RECOVER AF

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.